<VariationArchive RecordType="classified" VariationID="11104" VariationName="NM_000116.5(TAFAZZIN):c.634del (p.Leu212fs)" VariationType="Deletion" Accession="VCV000011104" Version="2" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-12-25" DateCreated="2022-03-28" MostRecentSubmission="2022-03-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="26143" VariationID="11104">
      <GeneList>
        <Gene Symbol="TAFAZZIN" FullName="tafazzin, phospholipid-lysophospholipid transacylase" GeneID="6901" HGNC_ID="HGNC:11577" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>Xq28</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="154411539" stop="154421726" display_start="154411539" display_stop="154421726" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="153639876" stop="153650064" display_start="153639876" display_stop="153650064" Strand="+" />
          </Location>
          <OMIM>300394</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000116.5(TAFAZZIN):c.634del (p.Leu212fs)</Name>
      <CanonicalSPDI>NC_000023.11:154420078:CCCC:CCC</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>Xq28</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="154420079" stop="154420079" display_start="154420079" display_stop="154420079" variantLength="1" positionVCF="154420078" referenceAlleleVCF="GC" alternateAlleleVCF="G" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="153648418" stop="153648418" display_start="153648418" display_stop="153648418" variantLength="1" positionVCF="153648417" referenceAlleleVCF="GC" alternateAlleleVCF="G" />
      </Location>
      <ProteinChange>L168fs</ProteinChange>
      <ProteinChange>L182fs</ProteinChange>
      <ProteinChange>L198fs</ProteinChange>
      <ProteinChange>L212fs</ProteinChange>
      <ProteinChange>L216fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_131" sequenceAccession="LRG_131">
            <Expression>LRG_131:g.13548del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_131t1" sequenceAccession="LRG_131t1">
            <Expression>LRG_131t1:c.634del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_131p1" sequenceAccession="LRG_131p1" change="p.Leu212fs">
            <Expression>LRG_131p1:p.Leu212fs</Expression>
          </ProteinExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009634.2" sequenceAccession="NG_009634" sequenceVersion="2" change="g.13548del">
            <Expression>NG_009634.2:g.13548del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.10" sequenceAccession="NC_000023" sequenceVersion="10" change="g.153648421del" Assembly="GRCh37">
            <Expression>NC_000023.10:g.153648421del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.11" sequenceAccession="NC_000023" sequenceVersion="11" change="g.154420082del" Assembly="GRCh38">
            <Expression>NC_000023.11:g.154420082del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000116.5" sequenceAccession="NM_000116" sequenceVersion="5" change="c.634del" MANESelect="true">
            <Expression>NM_000116.5:c.634del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000107.1" sequenceAccession="NP_000107" sequenceVersion="1" change="p.Leu212fs">
            <Expression>NP_000107.1:p.Leu212fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001303465.2" sequenceAccession="NM_001303465" sequenceVersion="2" change="c.646del">
            <Expression>NM_001303465.2:c.646del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001290394.1" sequenceAccession="NP_001290394" sequenceVersion="1" change="p.Leu216fs">
            <Expression>NP_001290394.1:p.Leu216fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_181311.4" sequenceAccession="NM_181311" sequenceVersion="4" change="c.544del">
            <Expression>NM_181311.4:c.544del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_851828.1" sequenceAccession="NP_851828" sequenceVersion="1" change="p.Leu182fs">
            <Expression>NP_851828.1:p.Leu182fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_181312.4" sequenceAccession="NM_181312" sequenceVersion="4" change="c.592del">
            <Expression>NM_181312.4:c.592del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_851829.1" sequenceAccession="NP_851829" sequenceVersion="1" change="p.Leu198fs">
            <Expression>NP_851829.1:p.Leu198fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_181313.4" sequenceAccession="NM_181313" sequenceVersion="4" change="c.502del">
            <Expression>NM_181313.4:c.502del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_851830.1" sequenceAccession="NP_851830" sequenceVersion="1" change="p.Leu168fs">
            <Expression>NP_851830.1:p.Leu168fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="NR_024048.3" sequenceAccession="NR_024048" sequenceVersion="3" change="n.955del">
            <Expression>NR_024048.3:n.955del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001619" Type="non-coding transcript variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="Allelic variant" ID="300394.0005" DB="OMIM" />
        <XRef Type="rs" ID="2148212610" DB="dbSNP" />
        <XRef ID="TAZ_000058" DB="LOVD 3" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000116.5(TAFAZZIN):c.634del (p.Leu212fs) AND 3-Methylglutaconic aciduria type 2" Accession="RCV000011853" Version="7">
        <ClassifiedConditionList TraitSetID="3071">
          <ClassifiedCondition DB="MedGen" ID="C0574083">3-Methylglutaconic aciduria type 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="1997-10-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="1997-10-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2022-03-28" MostRecentSubmission="2022-03-28">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">7616547</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9382096</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3071" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="487" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">3-methylglutaconicaciduria type II</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MGA type II</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cardioskeletal myopathy with neutropenia and abnormal mitochondria</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">3-Methylglutaconic aciduria type 2</ElementValue>
                <XRef ID="Barth+Syndrome/744" DB="Genetic Alliance" />
                <XRef ID="297231002" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Barth syndrome</ElementValue>
                <XRef ID="MONDO:0010543" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">MGCA2</ElementValue>
                <XRef Type="MIM" ID="302060" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">BTHS</ElementValue>
                <XRef Type="MIM" ID="302060" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">MGA2</ElementValue>
                <XRef Type="MIM" ID="302060" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5890" />
                <XRef ID="5890" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Barth syndrome is characterized in affected males by cardiomyopathy, neutropenia, skeletal myopathy, prepubertal growth delay, and distinctive facial gestalt (most evident in infancy); not all features may be present in a given affected male. Cardiomyopathy, which is almost always present before age five years, is typically dilated cardiomyopathy with or without endocardial fibroelastosis or left ventricular noncompaction; hypertrophic cardiomyopathy can also occur. Heart failure is a significant cause of morbidity and mortality; risk of arrhythmia and sudden death is increased. Neutropenia is most often associated with mouth ulcers, pneumonia, and sepsis. The nonprogressive myopathy predominantly affects the proximal muscles, and results in early motor delays. Prepubertal growth delay is followed by a postpubertal growth spurt with remarkable "catch-up" growth. Heterozygous females who have a normal karyotype are asymptomatic and have normal biochemical studies.</Attribute>
                <XRef ID="NBK247162" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301486</ID>
                <ID Source="BookShelf">NBK1309</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">25299040</ID>
                <ID Source="BookShelf">NBK247162</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C5-OH.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Elevated C5-OH Acylcarnitine, Organic Acidemias, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C5-OH-Elevated.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Organic Acidemias: Elevated C5-OH, 2022</CitationText>
              </Citation>
              <XRef ID="111" DB="Orphanet" />
              <XRef ID="C0574083" DB="MedGen" />
              <XRef ID="MONDO:0010543" DB="MONDO" />
              <XRef Type="MIM" ID="302060" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="32086" SubmissionDate="2022-03-21" DateLastUpdated="2022-03-28" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="300394.0005_BARTH SYNDROME" title="TAFAZZIN, 1-BP DEL_BARTH SYNDROME" />
        <ClinVarAccession Accession="SCV000032086" DateUpdated="2022-03-28" DateCreated="2013-04-04" Type="SCV" Version="3" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1997-10-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In affected members of a large Australian family in which males died in early infancy from congenital dilated cardiomyopathy (BTHS; 302060), originally reported by Gedeon et al. (1995), D'Adamo et al. (1997) identified a 1-bp deletion in exon 8 of the G4.5 gene, causing a frameshift and resulting in a stop codon after 18 nucleotides. The mutation caused knockout of all the putative tafazzins. The severe clinical manifestations of the disorder (described in 6 affected males and in 8 males suspected of being affected) could thus be related to the severity of the mutation.</Attribute>
              <Citation>
                <ID Source="PubMed">7616547</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">9382096</ID>
              </Citation>
              <XRef DB="OMIM" ID="302060" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TAFAZZIN" />
          </GeneList>
          <Name>TAFAZZIN, 1-BP DEL</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">1-BP DEL</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="300394.0005" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">BARTH SYNDROME</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="32086" TraitType="Disease" MappingType="Name" MappingValue="BARTH SYNDROME" MappingRef="Preferred">
        <MedGen CUI="C0574083" Name="3-Methylglutaconic aciduria type 2" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>